Guanfacine (DB01018): A Comprehensive Pharmacological and Clinical Monograph

I. Drug Identification and Physicochemical Profile

1.1. Overview and Classification

Guanfacine is a centrally acting sympatholytic agent, pharmacologically classified as a highly selective alpha-2A (α2A​) adrenergic receptor agonist.[1] Originally developed and approved for the treatment of hypertension, its distinct neuropharmacological properties, particularly its effects on the prefrontal cortex, have led to its successful repurposing for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in pediatric populations.[3] In the context of ADHD management, it is categorized as a non-stimulant medication, offering a distinct therapeutic alternative to traditional psychostimulants like methylphenidate and amphetamines.[5]

Under the Anatomical Therapeutic Chemical (ATC) classification system, guanfacine is assigned the code C02AC02. This places it in the therapeutic group for cardiovascular system drugs (C), specifically antihypertensives (C02), antiadrenergic agents with central action (C02A), and imidazoline receptor agonists (C02AC).[4] This classification reflects its initial development as an antihypertensive agent, though its modern clinical utility has expanded significantly into the realm of neuropsychiatry.

1.2. Nomenclature and Identifiers

The precise identification of a chemical entity is paramount in scientific and clinical discourse. Guanfacine is identified by a standardized set of names and codes to ensure unambiguous reference across global databases and scientific literature.

• DrugBank ID: DB01018 [3]
• CAS Number: The Chemical Abstracts Service (CAS) has assigned the number 29110-47-2 to the guanfacine free base.[1] The commonly used hydrochloride salt form is identified by CAS number 29110-48-3.[1] The distinction between the free base and its salt form is a critical detail for researchers and pharmaceutical scientists, as the specific form used can influence key physicochemical properties such as solubility, stability, and dissolution rate, which in turn affect formulation and bioavailability. Any rigorous interpretation of experimental or clinical data must account for the specific form of guanfacine being investigated to ensure accuracy and reproducibility.
• Chemical Names:
• The International Union of Pure and Applied Chemistry (IUPAC) name is N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide.[1]
• An alternate chemical name frequently used is N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide.[7]
• Synonyms and Development Codes: Throughout its development and across different regions, guanfacine has been known by various names and codes, including Guanfacina, Guanfacinum, BS 100-141, SPD 503, and NSC-759121.[1]

1.3. Chemical Structure and Physicochemical Properties

Guanfacine is a small molecule belonging to the class of acetamides.[4] Its structural and physical properties are summarized below:

• Chemical Formula: C9​H9​Cl2​N3​O [1]
• Molecular Weight: The average molecular weight is 246.09 g/mol.[1]
• Monoisotopic Mass: The precise monoisotopic mass is 245.012267339 Da.[3]
• Physical Description: In its solid state, guanfacine hydrochloride is a white or almost white crystalline powder.[10]
• Solubility: It is sparingly soluble in water and alcohol, slightly soluble in acetone, and readily soluble in dimethyl sulfoxide (DMSO).[1]
• Storage Conditions: For long-term preservation of chemical integrity, particularly in research settings, it is recommended to store guanfacine in a dry, dark environment at -20°C.[1]

The fundamental properties of guanfacine are consolidated in the table below for rapid reference.

Table 1: Guanfacine Identification and Physicochemical Properties

Property	Value	Source(s)
DrugBank ID	DB01018	3
CAS Number	29110-47-2 (free base)	1
Chemical Formula	C9​H9​Cl2​N3​O	3
Molecular Weight	246.09 g/mol (Average)	3
IUPAC Name	N-(aminoiminomethyl)-2,6-dichloro-benzeneacetamide	1
Common Synonyms	Guanfacina, BS 100-141, SPD 503	1
Physical Description	White or almost white crystalline powder	10
Solubility	Sparingly soluble in water and alcohol; Soluble in DMSO	1

II. Regulatory History and Formulations

The regulatory history of guanfacine illustrates a significant trend in modern pharmacology: the strategic repurposing of an established molecule for a new therapeutic indication, enabled by advancements in pharmaceutical formulation technology. This journey transformed guanfacine from a niche antihypertensive agent into a key non-stimulant treatment for ADHD.

2.1. Initial Approval for Hypertension (Tenex)

Guanfacine was first described in the scientific literature in 1974.[3] Following clinical development, it received its initial approval from the U.S. Food and Drug Administration (FDA) on October 27, 1986.[3] Marketed under the brand name Tenex, it was formulated as an immediate-release (IR) tablet and indicated for the management of hypertension.[12] The approved strengths of Tenex were 1 mg, 2 mg, and 3 mg.[11]

Although the brand-name product Tenex was eventually discontinued by its manufacturer, the FDA later conducted a review and determined that the withdrawal was not for reasons of safety or effectiveness.[11] This regulatory finding is significant because it allows for the continued marketing and approval of Abbreviated New Drug Applications (ANDAs) for generic immediate-release guanfacine tablets for hypertension.

2.2. Repurposing and Approval for ADHD (Intuniv)

The therapeutic potential of guanfacine beyond hypertension was first systematically explored for prefrontal cortex disorders by the Arnsten Lab at Yale University.[16] This foundational research into its neurobiological mechanisms paved the way for its development as a treatment for ADHD.

The primary challenge in repurposing guanfacine for chronic use in a pediatric population was managing its side effect profile, particularly the sedation and hypotension associated with the peak plasma concentrations of the IR formulation. This challenge was overcome through the development of an extended-release (ER) formulation by Shire plc, which was given the brand name Intuniv.[6]

Intuniv received its first FDA approval on September 2, 2009, as a monotherapy for the treatment of ADHD in children and adolescents aged 6 to 17 years.[6] The indication was later expanded on February 25, 2011, to include its use as an adjunctive therapy to psychostimulants in the same age group, providing a new option for patients with a suboptimal response to stimulant monotherapy.[18] Intuniv is available as 1 mg, 2 mg, 3 mg, and 4 mg extended-release tablets, with labeling that allows for dose increases up to 7 mg per day in adolescents based on weight and clinical response.[20]

The European Medicines Agency (EMA) followed with authorization for Intuniv in the European Union on September 17, 2015.[4] The first generic versions of Intuniv ER tablets were approved by the FDA in October 2015, increasing access to this formulation.[23]

This regulatory arc is a compelling case study in modern drug development. It began with a drug whose clinical utility was limited by its side effect profile. A deeper understanding of its specific neurobiological action in the prefrontal cortex, distinct from its effects on the brainstem, revealed a novel therapeutic application. However, this new application was only made clinically practical through pharmaceutical innovation—the creation of an extended-release delivery system. The ER formulation effectively smoothed the plasma concentration curve, mitigating the peak-dose adverse effects of sedation and hypotension while maintaining a therapeutic drug level suitable for once-daily dosing. This is crucial for ensuring adherence and tolerability in children and adolescents. The story of guanfacine is thus a prime example of how new biological insights combined with advanced drug delivery technology can unlock the full potential of an existing molecule.

2.3. Key Distinction Between Formulations

A critical point of emphasis for clinicians and pharmacists is that the immediate-release (Tenex and its generics) and extended-release (Intuniv and its generics) formulations of guanfacine are not bioequivalent and must not be substituted for one another on a milligram-per-milligram basis.[5] Their pharmacokinetic profiles are deliberately and substantially different. Consequently, switching a patient from an IR to an ER formulation requires a complete discontinuation of the IR product, followed by a new dose titration schedule starting from the initial dose of the ER product.[24] Failure to adhere to this guidance can result in either a loss of efficacy or significant adverse events.

III. Comprehensive Pharmacological Profile

3.1. Mechanism of Action

Guanfacine's diverse clinical applications in both hypertension and ADHD are not the result of interactions with multiple distinct receptors, but rather the consequence of its highly selective action on a single receptor subtype—the α2A​-adrenergic receptor—located in functionally distinct neural circuits.

3.1.1. Primary Target: The α2A​-Adrenergic Receptor

Guanfacine is a potent and highly selective agonist of the α2A​-adrenergic receptor, demonstrating low affinity for other adrenergic receptor subtypes (α2B​, α2C​) and non-adrenergic receptors.[8] This high degree of selectivity is a key pharmacological feature that distinguishes it from older, less selective

α2​-agonists like clonidine, and is thought to contribute to its more favorable side effect profile.[16]

3.1.2. Mechanism in Hypertension

The antihypertensive effect of guanfacine is mediated by its agonist activity at α2A​-adrenoceptors located within the central nervous system, particularly in brainstem nuclei such as the nucleus of the solitary tract. Activation of these presynaptic autoreceptors inhibits the firing of noradrenergic neurons, leading to a reduction in sympathetic outflow from the CNS to the periphery.[8] This decrease in central sympathetic tone results in reduced peripheral vascular resistance, a modest decrease in heart rate, and a subsequent lowering of both systolic and diastolic blood pressure.[2]

3.1.3. Mechanism in ADHD

The therapeutic mechanism in ADHD is fundamentally different and relies on guanfacine's action within the prefrontal cortex (PFC), the brain region responsible for executive functions, including attention, working memory, and impulse control. In contrast to its action in the brainstem, the benefits in ADHD are attributed to the stimulation of post-synaptic α2A​-adrenoceptors located on the dendritic spines of PFC pyramidal neurons.[16]

This post-synaptic receptor activation initiates a specific intracellular signaling cascade that is crucial for strengthening PFC network connectivity. Guanfacine's binding to these receptors inhibits the enzyme adenylyl cyclase, which leads to a decrease in the intracellular concentration of the second messenger cyclic adenosine monophosphate (cAMP).[16] Reduced cAMP levels cause the closure of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels and KCNQ potassium channels.[16] These channels, when open, act as a "leak," allowing potassium ions to flow out of the dendritic spines and weakening synaptic signals. By closing these channels, guanfacine effectively "plugs the leak," which strengthens synaptic connections, enhances the firing of PFC neurons in response to relevant stimuli, and improves the signal-to-noise ratio within cortical circuits.[16] This neurophysiological enhancement is believed to be the basis for the observed clinical improvements in attention, working memory, and behavioral inhibition in patients with ADHD.[16]

This elegant, circuit-specific pharmacology explains how a single drug can treat two seemingly unrelated conditions. The versatility of guanfacine is a direct result of the same molecular target (α2A​ receptor) playing fundamentally different roles in different parts of the brain: a sympatholytic role in the brainstem and a network-stabilizing, pro-cognitive role in the prefrontal cortex.

3.1.4. Secondary Targets and Potential Implications

While highly selective, guanfacine does interact with other receptors, though the clinical significance remains a subject of investigation.

• Serotonin 5-HT2B Receptor: Guanfacine has been identified as an agonist at the serotonin 5-HT2B receptor.[16] This is a noteworthy finding, as sustained agonism at this receptor by other drugs (e.g., fenfluramine) has been linked to a risk of cardiac valvulopathy. However, in vitro studies have provided some reassurance. Guanfacine's affinity for the 5-HT2B receptor is approximately 100-fold lower than its affinity for its primary α2A​ target, and its potency as a 5-HT2B agonist is about 1,000-fold lower than that of the endogenous ligand serotonin.[16] Based on these findings, it has been concluded that at clinically relevant plasma concentrations, significant 5-HT2B receptor activation is not expected, and the risk of cardiac valvulopathy is likely low. Despite a long history of clinical use without clear associations with this adverse event, definitive clinical data were still lacking as of 2018, and a theoretical risk, however small, cannot be entirely dismissed.[16]
• Trace Amine-Associated Receptor 1 (TAAR1): More recent research has found that guanfacine acts as a full agonist of TAAR1 with a high potency (EC50​ of 20 nM).[16] TAAR1 is an intracellular G-protein coupled receptor that modulates monoamine neurotransmission and is an area of active research in neuropsychiatry. The clinical implications of guanfacine's TAAR1 agonism are not yet understood but represent an important avenue for future investigation into its full pharmacological profile.

3.2. Pharmacodynamics

The observable physiological effects of guanfacine are direct consequences of its mechanism of action at α2A​-adrenergic receptors.

• Cardiovascular Effects: The most prominent and clinically significant pharmacodynamic effects are cardiovascular. Guanfacine causes dose-dependent decreases in blood pressure and heart rate (bradycardia).[3] These effects are most pronounced during the initial phase of treatment and after dose increases, necessitating careful dose titration and regular monitoring of vital signs.[24] In susceptible individuals, these effects can lead to clinically significant events such as orthostatic hypotension and syncope (fainting).[3]
• Central Nervous System Effects: The primary CNS effects are sedation, somnolence (drowsiness), and fatigue.[16] These are common, dose-related, and typically most intense during the first few weeks of therapy, after which tolerance often develops.[31] The drug also demonstrates anxiolytic-like properties, which are thought to result from its ability to dampen stress-induced catecholamine release and strengthen PFC-mediated top-down regulation of emotional centers like the amygdala.[16]

3.3. Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) profile of guanfacine is well-characterized, with critical differences between its immediate-release and extended-release formulations.

3.3.1. Absorption and Bioavailability

Guanfacine is readily absorbed after oral administration, with the immediate-release formulation having an absolute oral bioavailability of approximately 80%.[3] Peak plasma concentrations (

Cmax​) for the IR formulation are typically reached within 1 to 4 hours (Tmax​).[10]

3.3.2. Impact of Food

Food intake has a significant impact on the pharmacokinetics of the extended-release (Intuniv) formulation. Administration with a high-fat meal substantially increases the rate and extent of absorption, leading to an approximate 75% increase in Cmax​ and a 40% increase in the total drug exposure (AUC).[20] This rapid increase in drug levels can heighten the risk of adverse effects such as hypotension and sedation. Therefore, it is a key clinical directive that Intuniv should

not be administered with a high-fat meal.[13] Furthermore, because grapefruit juice is a potent inhibitor of the CYP3A4 enzyme responsible for guanfacine's metabolism, it should be avoided to prevent unpredictable increases in drug levels.[32]

3.3.3. Distribution

Guanfacine is approximately 70% bound to plasma proteins, a binding that is independent of drug concentration.[10] It has a large volume of distribution (mean of 6.3 L/kg), indicating extensive distribution into tissues throughout the body.[20]

3.3.4. Metabolism

Guanfacine undergoes extensive hepatic metabolism, primarily through oxidative pathways mediated by the cytochrome P450 3A4 (CYP3A4) isoenzyme.[5] This heavy reliance on a single, major metabolic pathway is the root of its vulnerability to numerous drug-drug interactions. Any co-administered substance that strongly inhibits or induces CYP3A4 activity can significantly alter guanfacine's plasma concentrations, leading to potential toxicity or loss of efficacy. This makes a thorough medication reconciliation, including over-the-counter products and herbal supplements (e.g., St. John's Wort), an essential safety step before and during guanfacine therapy.

3.3.5. Excretion

The elimination of guanfacine occurs through both metabolism and renal excretion of the unchanged drug. Approximately 50% of an administered dose is excreted in the urine as unchanged guanfacine, with the remainder eliminated as metabolites, primarily glucuronide and sulfate conjugates.[6] The elimination half-life (

t1/2​) in individuals with normal renal function is approximately 17 to 18 hours, with a range of 10 to 30 hours.[10]

3.3.6. Comparative Pharmacokinetics of IR vs. ER Formulations

The extended-release formulation was engineered to provide a smoother, more prolonged plasma concentration profile compared to the immediate-release version, thereby improving its tolerability for the treatment of ADHD. The key pharmacokinetic differences are substantial and clinically meaningful.

Table 2: Key Pharmacokinetic Parameters: Immediate-Release (IR) vs. Extended-Release (ER)

Parameter	Guanfacine IR (Tenex)	Guanfacine ER (Intuniv)	Clinical Implication
Tmax​ (Time to Peak)	~1–4 hours	~5–6 hours	ER formulation avoids a rapid peak, reducing acute side effects like sedation and dizziness.
Cmax​ (Peak Concentration)	Higher (e.g., 2.5 ng/mL for 1 mg)	~60% Lower (e.g., 1.0 ng/mL for 1 mg)	Lower peak concentration with ER further mitigates dose-related adverse events.
Bioavailability	~80% (Absolute)	~58% relative to IR (~43% lower)	A given mg dose of ER delivers less total drug than the same mg dose of IR; formulations are not interchangeable.
Half-life (t1/2​)	~17 hours (range 10-30)	~18 hours	Similar half-lives support once-daily dosing for both, but the ER profile provides more stable concentrations over 24 hours.
Food Effect	Not specified as clinically significant	Avoid high-fat meals (↑Cmax​ ~75%, ↑AUC ~40%)	The ER formulation's release matrix is disrupted by high-fat food, leading to dose-dumping and increased risk of toxicity.
Data primarily sourced from 10

3.3.7. Pharmacokinetics in Special Populations

• Renal Impairment: Guanfacine clearance is reduced in patients with renal impairment. While plasma levels are only slightly increased, it is recommended to use doses at the lower end of the therapeutic range.[3] Guanfacine is poorly removed by hemodialysis, so no supplemental dosing is required.[6]
• Hepatic Impairment: As guanfacine is extensively metabolized by the liver, dose reduction may be necessary in patients with significant hepatic impairment.[38]
• Pediatric Population: Pharmacokinetic studies have shown that, for a given dose of the ER formulation, drug exposure is approximately 40% higher in children (ages 6-12) compared to adolescents (ages 13-17), likely due to differences in body weight. This finding supports the use of weight-based dosing guidelines in pediatric patients.[18]

IV. Clinical Efficacy and Therapeutic Applications

Guanfacine's clinical utility spans two distinct therapeutic areas, hypertension and ADHD, with a growing body of research exploring its potential in other neuropsychiatric conditions characterized by prefrontal cortex dysfunction.

4.1. Approved Indications

4.1.1. Attention-Deficit/Hyperactivity Disorder (ADHD)

The primary modern application of guanfacine is in the treatment of ADHD. The extended-release formulation (Intuniv) is indicated for use in children and adolescents aged 6 to 17, both as a monotherapy and as an adjunctive treatment to psychostimulants.[3]

• Efficacy Data: The efficacy of guanfacine ER has been robustly established in a series of Phase 3 and 4 clinical trials.[41] In pivotal short-term (8-9 weeks), randomized, placebo-controlled trials, treatment with guanfacine ER at doses of 1 to 4 mg per day resulted in statistically and clinically significant reductions in ADHD symptoms. On the ADHD Rating Scale-IV (ADHD-RS-IV), a standard measure of symptom severity, guanfacine produced an average score reduction of 17 to 21 points from baseline, compared to a 9 to 12 point reduction observed with placebo.[31] The long-term benefit of the drug has been demonstrated in randomized-withdrawal studies, where patients who responded to open-label treatment and continued on guanfacine showed a significantly lower rate of relapse (treatment failure) compared to those switched to placebo.[41]
• Adjunctive Therapy: Guanfacine is also proven effective when added to a pre-existing psychostimulant regimen.[19] This provides a critical therapeutic option for the significant number of patients who experience only a partial response to stimulants alone. Guanfacine can be particularly helpful in managing residual symptoms of hyperactivity, impulsivity, and emotional dysregulation (e.g., emotional over-reactions, aggression) that may not be fully addressed by stimulant monotherapy.[45]
• Place in Therapy: Within the ADHD treatment algorithm, guanfacine ER is considered a first-line non-stimulant and a second-line agent overall.[5] It is a preferred option for patients who cannot tolerate stimulants due to adverse effects (e.g., appetite suppression, insomnia, anxiety), have an inadequate response, have a co-occurring condition for which stimulants are contraindicated, or for whom there is a concern for substance misuse.[5] Clinical trial data suggest that its efficacy may be most pronounced in pre-adolescent children (ages 6-12).[5]

4.1.2. Hypertension

The immediate-release formulation of guanfacine (Tenex and its generics) is indicated for the management of hypertension, either as a standalone treatment or in combination with other antihypertensive classes, particularly thiazide-type diuretics.[10]

• Efficacy Data: Dose-response studies have confirmed its antihypertensive effects, with a clinically useful reduction in blood pressure typically observed at doses of 1 to 2 mg per day. Ambulatory blood pressure monitoring has documented that once-daily dosing can maintain effectiveness over a full 24-hour period.[10]
• Place in Therapy: Despite its proven efficacy, guanfacine is no longer considered a first-line agent for the treatment of essential hypertension according to major clinical guidelines.[40] The development of newer classes of antihypertensives—such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers—with more favorable side effect profiles and robust evidence for reducing cardiovascular morbidity and mortality has relegated centrally acting agents to a lower tier.[46] Guanfacine is now typically reserved for cases of resistant hypertension where multiple other agents have failed or are contraindicated, or in specific clinical scenarios where its sympatholytic properties may be desirable.[48]

4.2. Off-Label and Investigational Uses

The unique mechanism of guanfacine as a modulator of PFC function has spurred significant interest in its use for a variety of other conditions. This expanding list of applications points toward a conceptual shift in viewing the drug not merely by its approved indications, but as a "PFC network stabilizer" with potential utility in any disorder involving compromised executive function.

• Established Off-Label Uses: Clinicians frequently use guanfacine off-label to treat tic disorders (including Tourette's syndrome), various anxiety disorders, and Post-Traumatic Stress Disorder (PTSD).[16] Its efficacy in these conditions is believed to stem from its ability to strengthen PFC-mediated top-down control over emotional and motor circuits, as well as its anxiolytic properties and its ability to improve sleep quality by reducing the frequency of nightmares in PTSD.[16]
• Emerging Research and Investigational Areas:
• Autism Spectrum Disorders (ASD) and Pervasive Developmental Disorders (PDD): Clinical trials are actively investigating guanfacine's efficacy in managing core behavioral challenges associated with ASD and PDD, such as hyperactivity, irritability, aggression, and repetitive behaviors.[50]
• Prader-Willi Syndrome (PWS): A recent randomized, double-blind, placebo-controlled trial (NCT05657860) provided strong evidence for the efficacy of guanfacine ER in this rare genetic disorder. The study found significant reductions in aggression, agitation, hyperactivity, and self-injurious behaviors (specifically skin-picking) compared to placebo.[52]
• Post-COVID Cognitive Impairment ("Brain Fog"): Pioneering case-series research from Yale University has explored a combination therapy of guanfacine and the antioxidant N-acetylcysteine (NAC) for the treatment of persistent cognitive deficits following COVID-19 infection. The hypothesis is that guanfacine strengthens PFC network connections that may be disrupted by neuroinflammation, while NAC provides a protective antioxidant effect. Initial results in a small cohort were promising, showing substantial improvements in memory and executive function.[53]
• Traumatic Brain Injury (TBI) and Stroke: Preclinical and clinical evidence suggests that TBI can lead to PFC dysfunction. Guanfacine is being investigated as a potential therapy to restore cognitive function, such as working memory, in these patients.[51] Similarly, a clinical trial has explored its use for treating spatial neglect following stroke.[54]
• Alzheimer's Disease: Recognizing the role of noradrenergic system dysfunction in the pathophysiology of Alzheimer's disease, a clinical trial has been initiated to evaluate the potential of extended-release guanfacine to improve cognitive and behavioral symptoms in this population.[54]

This broad range of investigational uses underscores the modern understanding of guanfacine's mechanism. The common thread linking ADHD, PTSD, TBI, and even post-viral brain fog is a disruption of the delicate neurocircuitry of the prefrontal cortex. Guanfacine's ability to directly target and strengthen these circuits makes it a promising therapeutic tool for a spectrum of disorders characterized by executive dysfunction.

Table 3: Summary of Pivotal Clinical Trials of Guanfacine ER (Intuniv) in ADHD

Study Identifier	Phase	Design	Population (N, Age)	Treatment Arms	Duration	Primary Outcome	Key Result (vs. Placebo)	Source(s)
NCT00152009	3	Randomized, Double-Blind, Placebo-Controlled, Dose-Optimization	N=345 (6-17 yrs)	GXR (2, 3, 4 mg/day), Placebo	8 weeks	Change in ADHD-RS-IV Total Score	Significant reduction from baseline (e.g., -10.39 points for 4mg dose; p < 0.0001)	6
NCT00734578	3	Randomized, Double-Blind, Placebo-Controlled (Adjunctive to Stimulant)	N=461 (6-17 yrs)	GXR (1-4 mg/day) + Stimulant, Placebo + Stimulant	9 weeks	Change in ADHD-RS-IV Total Score	Significant additional reduction in symptoms compared to stimulant alone	19
NCT01081145	3	Randomized-Withdrawal, Double-Blind, Placebo-Controlled	N=526 (6-17 yrs)	Open-label GXR followed by randomization to GXR or Placebo	26 weeks	Time to Treatment Failure	Significantly lower rate of treatment failure for patients continuing GXR (49.3%) vs. Placebo (64.9%)	41
NCT01244490	3	Randomized, Double-Blind, Placebo- and Active-Controlled	N=338 (6-17 yrs)	GXR (1-7 mg/day), Atomoxetine, Placebo	10-13 weeks	Change in ADHD-RS-IV Total Score	GXR (-23.9 points) superior to Atomoxetine (-18.6) and Placebo (-15.0)	32
SPD503-317 (Japan)	3	Randomized, Double-Blind, Placebo-Controlled (Adults)	N=201 (≥18 yrs)	GXR (4-6 mg/day), Placebo	10 weeks	Change in ADHD-RS-IV Total Score	Significant reduction in symptoms from baseline (-16.7) vs. Placebo (-9.3)	57

V. Safety, Tolerability, and Risk Management

The safe and effective use of guanfacine requires a thorough understanding of its adverse effect profile, potential for drug interactions, and specific considerations for different patient populations. A proactive and structured clinical management approach is essential to optimize the risk-benefit ratio of this medication.

5.1. Adverse Effect Profile

5.1.1. Common Adverse Events

The most frequently reported adverse effects associated with guanfacine are generally mild to moderate in severity, dose-related, and often transient, tending to diminish with continued therapy over several weeks.[31] These include:

• Central Nervous System: The most common adverse events are CNS-related. Somnolence (drowsiness), sedation, and fatigue are very common, reported in up to 40% of children in clinical trials, and are the most frequent reasons for treatment discontinuation.[14] Headache and dizziness are also frequently reported.[29]
• Gastrointestinal: Dry mouth (xerostomia) is a very common side effect. Constipation, nausea, and upper abdominal pain also occur frequently.[13]
• Metabolic: Decreased appetite is a common finding. Unlike stimulants, which often cause weight loss, guanfacine has been associated with a potential for modest weight gain in some patients.[13]

5.1.2. Serious Adverse Events

While less common, guanfacine is associated with several potentially serious adverse events that require careful monitoring.

• Cardiovascular: The most significant risks are cardiovascular. Dose-dependent hypotension (low blood pressure) and bradycardia (slow heart rate) are expected pharmacodynamic effects. In some patients, these can lead to orthostatic hypotension (dizziness upon standing) and syncope (fainting).[3] Due to these risks, it is imperative to measure blood pressure and heart rate at baseline, following each dose increase, and periodically throughout treatment.[24] The risk is elevated in patients with pre-existing conditions such as heart block, bradycardia, or other cardiovascular diseases.[29]
• Psychiatric: Although rare, there have been postmarketing reports of mania, aggressive behavioral changes, and hallucinations, primarily in pediatric patients being treated for ADHD.[58] Many of these cases occurred in children with pre-existing medical or family risk factors for bipolar disorder.[59]

5.1.3. Discontinuation and Rebound Phenomena

Abrupt cessation of guanfacine therapy is hazardous and must be avoided. Sudden discontinuation can lead to a withdrawal syndrome characterized by a rapid increase in sympathetic tone, resulting in nervousness, anxiety, and, most importantly, rebound hypertension, where blood pressure can rise to levels significantly above the pre-treatment baseline.[13] To prevent this, treatment must always be discontinued via a gradual dose taper. The recommended tapering schedule is to decrease the daily dose in increments of no more than 1 mg every 3 to 7 days, with continued monitoring of blood pressure and pulse.[21]

5.2. Drug Interactions

Guanfacine's heavy reliance on the CYP3A4 metabolic pathway and its intrinsic pharmacodynamic effects on the CNS and cardiovascular system create a high potential for clinically significant drug-drug interactions.

5.2.1. Pharmacokinetic Interactions (CYP3A4-Mediated)

• Strong and Moderate CYP3A4 Inhibitors: Co-administration of guanfacine with potent inhibitors of the CYP3A4 enzyme will significantly decrease its metabolism, leading to higher plasma concentrations and an increased risk of adverse effects like hypotension, bradycardia, and sedation. Examples include azole antifungals (e.g., ketoconazole), macrolide antibiotics (e.g., clarithromycin), certain antivirals (e.g., ritonavir), and grapefruit juice.[5] When such an inhibitor is initiated, the guanfacine dose should be reduced by 50%.[38]
• Strong and Moderate CYP3A4 Inducers: Conversely, co-administration with strong inducers of CYP3A4 will accelerate guanfacine's metabolism, leading to lower plasma concentrations and a potential loss of therapeutic efficacy. Examples include certain anticonvulsants (e.g., carbamazepine, phenytoin), rifampin, and the herbal supplement St. John's Wort.[5] When an inducer is initiated, it may be necessary to consider doubling the recommended guanfacine dose over one to two weeks.[38]

5.2.2. Pharmacodynamic Interactions

• Central Nervous System (CNS) Depressants: Guanfacine has additive sedative effects when combined with other CNS depressants. This includes alcohol, benzodiazepines, opioids, barbiturates, muscle relaxants, and sedating antihistamines.[29] Patients must be counseled to avoid alcohol and to exercise extreme caution when operating heavy machinery or driving until they understand how the combination affects them.[14]
• Antihypertensives and Bradycardic Agents: When used with other drugs that lower blood pressure (e.g., diuretics, ACE inhibitors, beta-blockers) or slow heart rate (e.g., beta-blockers, digoxin, certain calcium channel blockers like verapamil and diltiazem), there is an increased risk of additive effects, leading to severe hypotension, bradycardia, or syncope.[5] Careful monitoring is required.
• Valproic Acid: There is evidence that co-administration of guanfacine can increase the plasma concentrations of valproic acid, an anticonvulsant and mood stabilizer. Monitoring of valproic acid levels may be warranted.[5]

Table 4: Clinically Significant Drug Interactions and Management Recommendations

Interacting Agent Class	Example Drugs	Mechanism	Effect on Guanfacine	Clinical Management	Source(s)
Strong/Moderate CYP3A4 Inhibitors	Ketoconazole, Clarithromycin, Ritonavir, Grapefruit juice	Pharmacokinetic: Inhibition of metabolism	Increased plasma concentration; increased risk of toxicity (hypotension, sedation)	Reduce guanfacine dose by 50%.	24
Strong/Moderate CYP3A4 Inducers	Carbamazepine, Phenytoin, Rifampin, St. John's Wort	Pharmacokinetic: Induction of metabolism	Decreased plasma concentration; potential loss of efficacy	Consider doubling the guanfacine dose over 1-2 weeks.	24
CNS Depressants	Alcohol, Benzodiazepines (e.g., Alprazolam), Opioids, Sedating Antihistamines (e.g., Diphenhydramine)	Pharmacodynamic: Additive sedative effects	Increased risk of somnolence, dizziness, cognitive/motor impairment	Counsel patient to avoid alcohol. Use combination with extreme caution. Warn against driving or operating machinery.	29
Other Antihypertensives / Bradycardic Agents	Beta-blockers (e.g., Metoprolol), Calcium Channel Blockers (e.g., Verapamil), Diuretics	Pharmacodynamic: Additive cardiovascular effects	Increased risk of hypotension, bradycardia, heart block, syncope	Use with caution. Monitor blood pressure and heart rate closely, especially during dose titration.	5

5.3. Contraindications, Warnings, and Use in Special Populations

• Contraindications: The only absolute contraindication is a history of a known hypersensitivity reaction to guanfacine or any of its inactive ingredients.[10]
• Warnings and Precautions: Guanfacine should be used with caution in patients with a history of hypotension, bradycardia, heart block, or syncope. Caution is also warranted in patients with underlying conditions that could be worsened by these cardiovascular effects, such as severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, or chronic renal or hepatic failure.[5]
• Pediatric Use: The extended-release formulation (Intuniv) is FDA-approved for ADHD in patients aged 6 to 17.[6] The immediate-release formulation is not recommended for treating hypertension in children younger than 12 years due to a lack of established safety and efficacy data.[39]
• Geriatric Use: Elderly patients may be more susceptible to the adverse effects of guanfacine, particularly sedation, dizziness, and orthostatic hypotension. Therefore, treatment in this population should be approached with caution, typically starting at the lowest possible dose and titrating slowly.[13] While not approved for this use, some case reports have explored its potential for managing agitation in elderly patients with dementia, but this remains an investigational area requiring careful risk-benefit assessment.[70]
• Pregnancy and Lactation:
• Pregnancy: Guanfacine is designated as US FDA Pregnancy Category B.[31] This classification is based on animal reproduction studies that failed to demonstrate a risk to the fetus; however, there are no adequate and well-controlled studies in pregnant humans.[72] Data on human exposure are extremely limited and insufficient to definitively assess risk.[49] Therefore, guanfacine should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential, though largely unknown, risk to the fetus.
• Lactation: It is not known whether guanfacine is excreted into human breast milk, although it has been detected in the milk of lactating rats.[72] Given the lack of human data and the potential for adverse effects in the nursing infant (such as sedation, lethargy, and hypotension), alternative medications with better-established safety profiles during breastfeeding are generally preferred.[49]

The safety profile of guanfacine mandates a structured, process-oriented approach to its clinical use. The management of this drug can be conceptualized across a therapeutic "life cycle," with distinct risks and corresponding management strategies at each stage. The initiation phase is dominated by the risks of sedation and hypotension, which must be managed with a slow and careful dose titration.[24] During the

maintenance phase, the primary challenge becomes vigilance for drug-drug interactions, requiring continuous medication reconciliation and patient education on potential interactants like grapefruit juice and St. John's Wort.[24] Finally, the

discontinuation phase carries the significant risk of rebound hypertension, which must be mitigated by a mandatory gradual dose taper.[13] This life-cycle perspective frames the safe use of guanfacine not as a single prescriptive act, but as a dynamic process of clinical management that continues for the entire duration of therapy.

VI. Comparative Therapeutic Analysis

To fully appreciate guanfacine's role in modern pharmacotherapy, it is essential to compare it to other agents used for the same indications. This analysis highlights the specific mechanistic and clinical features that define its unique therapeutic niche.

6.1. Guanfacine vs. Clonidine

Guanfacine and clonidine are the two primary α2​-adrenergic agonists used in clinical practice. While they share a general mechanism, their differences in receptor selectivity and pharmacokinetics lead to important distinctions in their clinical profiles.

• Mechanism and Selectivity: The most critical difference lies in their receptor binding profiles. Guanfacine is a highly selective agonist for the α2A​-adrenergic receptor subtype. In contrast, clonidine is a non-selective agonist, binding with high affinity to all three α2​ subtypes (α2A​, α2B​, and α2C​) as well as to imidazoline receptors.[16] It is hypothesized that the sedative and hypotensive effects of these drugs are mediated not only by α2A​ receptors but also by α2B/2C​ and imidazoline receptors. Guanfacine's greater selectivity for the α2A​ subtype—the primary target for cognitive enhancement in the PFC—is thought to be the reason for its more favorable tolerability profile compared to clonidine.[16]
• Pharmacokinetics: Guanfacine possesses a longer elimination half-life (approximately 17-18 hours) than clonidine.[3] This longer duration of action was a key factor in the development of a successful once-daily extended-release formulation (Intuniv) for ADHD, which improves convenience and adherence.
• Efficacy: For ADHD, both medications are considered effective non-stimulant options.[28] Some evidence suggests that guanfacine's more targeted action in the PFC may confer specific advantages in improving executive functions like working memory and planning.[77] For hypertension, both provide effective blood pressure reduction. However, guanfacine's longer half-life and once-daily dosing may offer smoother 24-hour blood pressure control with fewer fluctuations compared to the multiple daily doses often required for immediate-release clonidine.[48]
• Tolerability and Safety: Guanfacine is generally associated with lower rates of sedation, drowsiness, and dizziness than clonidine.[16] This improved tolerability is attributed to its α2A​ selectivity and weaker presynaptic action.[16] Furthermore, while both drugs carry a risk of rebound hypertension upon abrupt withdrawal, this phenomenon may be less severe and have a more delayed onset (day 4 for guanfacine vs. day 2 for clonidine) with guanfacine, again owing to its longer half-life.[62]

Table 5: Comparative Profile of Guanfacine and Clonidine

Feature	Guanfacine	Clonidine
Primary Mechanism	Central α2​-Adrenergic Agonist	Central α2​-Adrenergic Agonist
Receptor Selectivity	Highly selective for α2A​ subtype	Non-selective for α2A​, α2B​, α2C​; also binds imidazoline receptors
Elimination Half-Life	~17–18 hours	Shorter; requires more frequent dosing for IR form
Dosing Frequency (ADHD)	Once daily (ER formulation)	Twice daily (ER formulation)
Relative Sedation	Less sedating	More sedating
Relative Hypotension	Less hypotensive	More hypotensive
Rebound Hypertension Risk	Present; may be less severe and delayed onset	Present; may be more severe and rapid onset
Data sourced from 16

6.2. Guanfacine vs. Other Non-Stimulant ADHD Medications

6.2.1. Atomoxetine (Strattera)

• Mechanism: Guanfacine and atomoxetine represent two distinct mechanistic classes of non-stimulant ADHD medication. Atomoxetine is a selective norepinephrine reuptake inhibitor (SNRI), which acts presynaptically to block the norepinephrine transporter (NET), thereby increasing the synaptic concentration of norepinephrine.[83] In contrast, guanfacine acts postsynaptically as a direct α2A​ receptor agonist.[16]
• Efficacy: Both are established as effective non-stimulants for ADHD. Direct head-to-head trials are lacking, but an indirect comparative analysis using the Matching-Adjusted Indirect Comparison (MAIC) methodology suggested that guanfacine ER may be more efficacious than atomoxetine in reducing total ADHD-RS-IV scores.[87] A large network meta-analysis found that while both were superior to placebo, they were generally less effective than stimulant medications for short-term symptom reduction.[88]
• Tolerability and Safety: The side effect profiles differ significantly. Guanfacine's primary adverse effects are sedation, fatigue, and cardiovascular effects (hypotension, bradycardia).[83] Atomoxetine is more commonly associated with gastrointestinal side effects (nausea, abdominal pain), decreased appetite, and insomnia.[83] Critically, atomoxetine carries an FDA boxed warning regarding an increased risk of suicidal ideation in children and adolescents, as well as warnings for severe liver injury, risks not associated with guanfacine.[85]

6.2.2. Viloxazine (Qelbree)

Viloxazine is another SNRI, making its mechanism of action more similar to atomoxetine than to guanfacine.[60] As a newer agent, direct comparative efficacy and tolerability data against guanfacine are limited.

This comparative analysis defines guanfacine's unique therapeutic niche. Within the α2​-agonist class, it offers a more refined and tolerable profile than clonidine. Compared to the SNRI non-stimulants, it provides a different, postsynaptic mechanism of action and a distinct safety profile that avoids the specific warnings associated with atomoxetine. This allows for a more individualized approach to non-stimulant therapy, where the choice of agent can be tailored to the patient's specific symptom cluster (e.g., α2​-agonists may be preferred for comorbid tics), tolerability concerns, and overall medical history.

6.3. Guanfacine's Role Among Antihypertensive Agents

As an antihypertensive, guanfacine is a member of the centrally acting alpha-2 receptor agonist class, which also includes clonidine and methyldopa.[92] While effective at lowering blood pressure, this class is no longer recommended as a first- or even second-line treatment for most patients with hypertension by major clinical guidelines, such as the 2017 ACC/AHA guideline.[37]

The standard of care for hypertension has shifted towards agents with more robust evidence of reducing long-term cardiovascular morbidity and mortality, including thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers.[46] The side effect profile of centrally acting agents, particularly sedation, dry mouth, and the risk of rebound hypertension, makes them less favorable for long-term use compared to these newer classes.[48] Consequently, guanfacine's role in hypertension management is now limited, typically reserved as a third- or fourth-line agent for patients with resistant hypertension who have not achieved their blood pressure goals with a multi-drug regimen of preferred agents.[48]

VII. Synthesis and Future Directions

7.1. Consolidated Risk-Benefit Assessment

Guanfacine presents a complex but valuable profile as a therapeutic agent. Its clinical utility is defined by a highly specific mechanism of action that must be balanced against a demanding set of management requirements.

• Benefits:
• ADHD: Guanfacine is a proven, effective non-stimulant medication for ADHD in children and adolescents, demonstrating significant efficacy both as monotherapy and as an adjunctive therapy.[19] It provides a crucial alternative for the 15-30% of patients who do not respond to or cannot tolerate stimulant medications.[45] Its mechanism is particularly well-suited for addressing symptoms of hyperactivity, impulsivity, and emotional dysregulation.[45] As a non-controlled substance, it has a low potential for abuse or dependence, a significant advantage over stimulants.[45]
• Hypertension: It is an effective antihypertensive agent, though its clinical role is now limited to that of a lower-tier, last-resort option due to its side effect profile.[48]
• Risks:
• The primary risks are dose-dependent and largely predictable. Cardiovascular effects, including hypotension, bradycardia, and syncope, and CNS effects, primarily sedation and fatigue, are the most common and clinically significant.[16] These risks are manageable through careful clinical practice, including slow dose titration and regular monitoring.
• The risk of rebound hypertension upon abrupt discontinuation is a serious safety concern that necessitates a mandatory gradual dose taper.[13]
• The high potential for clinically significant drug-drug interactions, mediated primarily by the CYP3A4 enzyme system, requires constant clinical vigilance.[24]
• A theoretical risk of 5-HT2B-mediated cardiac valvulopathy exists but is considered low based on preclinical data.[16]

The overall profile of guanfacine is that of a highly targeted but demanding medication. Its efficacy is rooted in an elegant neurobiological mechanism, but unlocking that efficacy safely requires a high degree of clinical sophistication. The risk-benefit ratio is not a static property of the drug itself but is a dynamic variable that is actively optimized by the skill of the prescribing clinician and the engagement of the patient. It is a powerful therapeutic tool, but one that demands expertise to be wielded safely and effectively.

7.2. Summary of Key Clinical Considerations

For the prescribing clinician, the safe and effective use of guanfacine can be distilled into the following essential practices:

1. Differentiate Formulations: Always distinguish between the immediate-release (IR) formulation for hypertension and the extended-release (ER) formulation for ADHD. They are not interchangeable.[5]
2. Titrate Slowly: Initiate therapy at a low dose (e.g., 1 mg/day for ER) and titrate upwards in slow increments (e.g., no more than 1 mg/week for ER) to maximize tolerability and minimize the risk of sedation and hypotension.[21]
3. Monitor Vital Signs: Measure blood pressure and heart rate at baseline, after every dose increase, and periodically throughout the course of therapy.[24]
4. Manage Drug Interactions: Conduct a thorough medication reconciliation at baseline and at subsequent visits. Be vigilant for potential interactions with CYP3A4 inhibitors and inducers, and make the necessary dose adjustments as recommended in the prescribing information.[38]
5. Provide Patient Counseling: Instruct patients to avoid taking the ER formulation with high-fat meals or grapefruit juice. Emphatically warn against the concurrent use of alcohol and other CNS depressants.[26]
6. Taper Upon Discontinuation: Never stop guanfacine abruptly. A gradual dose reduction over several weeks is mandatory to prevent rebound hypertension.[21]

7.3. Outlook on Ongoing Research and Future Therapeutic Potential

The evolution of guanfacine from an antihypertensive to a neuropsychiatric agent is likely not its final chapter. The growing understanding of its function as a modulator of prefrontal cortex network activity is driving its investigation into a new wave of potential indications.

• Emerging Indications: Promising preliminary data in conditions such as post-COVID cognitive dysfunction ("brain fog"), the behavioral symptoms of Prader-Willi syndrome, and agitation in dementia suggest a much broader future role for guanfacine.[52] Its potential as a "pro-cognitive" or "PFC-stabilizing" agent could extend to any condition where executive function is compromised by stress, inflammation, or neurodegeneration.
• Future Research Needs: The path forward for guanfacine will require rigorous scientific investigation. Key areas for future research include:
• Conducting large-scale, randomized, placebo-controlled trials to confirm its efficacy and safety in these emerging indications.
• Further elucidating the clinical relevance of its activity at secondary targets, such as TAAR1, to better understand its complete mechanism of action.[16]
• Performing direct head-to-head comparative trials against other non-stimulant ADHD medications to more clearly define its relative strengths and weaknesses and to better guide individualized treatment selection.[31]
• Initiating long-term safety studies to provide more definitive data on its cardiovascular and metabolic effects with chronic use.

In conclusion, guanfacine is a well-established medication that continues to reveal new therapeutic potential. Its journey from a simple antihypertensive to a sophisticated modulator of cortical function is a testament to the progress of neuropharmacology. While its use demands careful and knowledgeable clinical management, its unique mechanism of action ensures it will remain a valuable and evolving tool in the treatment of ADHD and, potentially, a growing number of other disorders of the central nervous system.

Works cited

1. Guanfacine | CAS# 29110-47-2 | Biochemical - MedKoo Biosciences, accessed August 3, 2025, [https://www.medkoo.com/products/44406]
2. medlineplus.gov, accessed August 3, 2025, [https://medlineplus.gov/druginfo/meds/a601059\.html\#:\~:text\=Guanfacine%20is%20in%20a%20class,more%20easily%20through%20the%20body.]
3. Guanfacine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 3, 2025, [https://go.drugbank.com/drugs/DB01018]
4. Guanfacine | C9H9Cl2N3O | CID 3519 - PubChem, accessed August 3, 2025, [https://pubchem.ncbi.nlm.nih.gov/compound/Guanfacine]
5. Guanfacine: ADHD Medication, Effects, and Options - Healthline, accessed August 3, 2025, [https://www.healthline.com/health/guanfacine\-adhd]
6. Guanfacine Extended-Release Tablets (Intuniv), a Nonstimulant Selective Alpha2A-Adrenergic Receptor Agonist For Attention-Deficit/Hyperactivity Disorder - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2935643/]
7. Guanfacine | CAS 29110-47-2 | SCBT - Santa Cruz Biotechnology, accessed August 3, 2025, [https://www.scbt.com/p/guanfacine\-29110\-47\-2]
8. Guanfacine | CAS NO.:29110-47-2 - GlpBio, accessed August 3, 2025, [https://www.glpbio.com/guanfacine.html]
9. Drug Information | Therapeutic Target Database, accessed August 3, 2025, [https://db.idrblab.net/ttd/data/drug/details/d8ny3j]
10. Guanfacine: Package Insert / Prescribing Information - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/pro/guanfacine.html]
11. Generic Tenex Availability - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/availability/generic\-tenex.html]
12. en.wikipedia.org, accessed August 3, 2025, [https://en.wikipedia.org/wiki/Guanfacine\#:\~:text\=Guanfacine%2C%20sold%20under%20the%20brand,ADHD)%20and%20high%20blood%20pressure.]
13. Guanfacine: MedlinePlus Drug Information, accessed August 3, 2025, [https://medlineplus.gov/druginfo/meds/a601059\.html]
14. DESCRIPTION Tenex (guanfacine hydrochloride) is a centrally ..., accessed August 3, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2013/019032s021lbl.pdf]
15. Determination That TENEX (Guanfacine Hydrochloride) Tablets, 1 Milligram, 2 Milligrams, and 3 Milligrams, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness - Federal Register, accessed August 3, 2025, [https://www.federalregister.gov/documents/2020/06/24/2020\-13594/determination\-that\-tenex\-guanfacine\-hydrochloride\-tablets\-1\-milligram\-2\-milligrams\-and\-3\-milligrams]
16. Guanfacine - Wikipedia, accessed August 3, 2025, [https://en.wikipedia.org/wiki/Guanfacine]
17. Intuniv (guanfacine) FDA Approval History - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/history/intuniv.html]
18. Cross Discipline Team Leader Review (Intuniv) - FDA, accessed August 3, 2025, [https://www.fda.gov/media/146820/download]
19. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for ADHD Treatment | Fierce Biotech, accessed August 3, 2025, [https://www.fiercebiotech.com/biotech/fda\-approves\-intuniv%C2%AE\-guanfacine\-extended\-release\-tablets\-for\-use\-as\-adjunctive\-therapy\-to]
20. Guanfacine Uses, Side Effects & Warnings - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/mtm/guanfacine.html]
21. Guanfacine (Intuniv) | National Alliance on Mental Illness (NAMI), accessed August 3, 2025, [https://www.nami.org/about\-mental\-illness/treatments/mental\-health\-medications/types\-of\-medication/guanfacine\-intuniv/]
22. N22-037 S011 Guanfacine Clinical PREA - FDA, accessed August 3, 2025, [https://www.fda.gov/files/drugs/published/N22\-037\-S011\-Guanfacine\-Clinical\-PREA.pdf]
23. Impax Receives FDA Approval for Generic Version of Intuniv® (Guanfacine) Extended-Release Tablets, 1 mg, 2 mg, 3 mg and 4 mg, accessed August 3, 2025, [https://investors.amneal.com/news/press\-releases/press\-release\-details/2015/Impax\-Receives\-FDA\-Approval\-for\-Generic\-Version\-of\-Intuniv\-Guanfacine\-Extended\-Release\-Tablets\-1\-mg\-2\-mg\-3\-mg\-and\-4\-mg/default.aspx]
24. Guanfacine XR | Intuniv Prescribing Information - MedWorks Media, accessed August 3, 2025, [https://medworksmedia.com/resources/psychotropics\-a\-z/psychotropic\-prescribing\-information/guanfacine\-xr\-intuniv/]
25. Reference ID: 2908375 - accessdata.fda.gov, accessed August 3, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2011/022037s002lbl.pdf]
26. INTUNIV (guanfacine) extended-release tablets - accessdata.fda.gov, accessed August 3, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2013/022037s009lbl.pdf]
27. Guanfacine | α2A Agonist - MedchemExpress.com, accessed August 3, 2025, [https://www.medchemexpress.com/guanfacine.html]
28. What is the mechanism of action of clonidine (antihypertensive medication) and guanfacine (alpha-2 adrenergic receptor agonist)? - Dr.Oracle, accessed August 3, 2025, [https://www.droracle.ai/articles/68598/what\-is\-mechanism\-of\-action\-of\-clonidine\-and\-guanfacine]
29. Guanfacine (oral route) - Side effects & dosage - Mayo Clinic, accessed August 3, 2025, [https://www.mayoclinic.org/drugs\-supplements/guanfacine\-oral\-route/description/drg\-20064131]
30. Profile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC4455846/]
31. Guanfacine (Intuniv) for Attention-Deficit/Hyperactivity Disorder - AAFP, accessed August 3, 2025, [https://www.aafp.org/pubs/afp/issues/2011/0215/p468\.html]
32. Guanfacine hydrochloride for attention deficit hyperactivity disorder - PMC - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC6091781/]
33. Guanfacine and Alcohol/Food Interactions - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/food\-interactions/guanfacine.html]
34. Guanfacine Hcl Er Food, Alcohol, Supplements and Drug Interactions, accessed August 3, 2025, [https://www.wellrx.com/guanfacine\-hcl\-er/lifestyle\-interactions/]
35. Guanfacine - LiverTox - NCBI Bookshelf, accessed August 3, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK548586/]
36. Intuniv (guanfacine): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 3, 2025, [https://www.rxlist.com/intuniv\-drug.htm]
37. Guanfacine: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed August 3, 2025, [https://www.medcentral.com/drugs/monograph/5481\-308013/guanfacine\-oral]
38. Intuniv(guanfacine) dosing, indications, interactions, adverse effects, and more, accessed August 3, 2025, [https://reference.medscape.com/drug/intuniv\-guanfacine\-342384]
39. Guanfacine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 3, 2025, [https://www.rxlist.com/guanfacine/generic\-drug.htm]
40. Guanfacine Monograph for Professionals - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/monograph/guanfacine.html]
41. Attention Deficit Hyperactivity Disorder (ADHD) Completed Phase 3 Trials for Guanfacine (DB01018) | DrugBank Online, accessed August 3, 2025, [https://go.drugbank.com/indications/DBCOND0041782/clinical\_trials/DB01018?phase\=3\&status\=completed]
42. Guanfacine Completed Phase 4 Trials for Attention Deficit Hyperactivity Disorder (ADHD) Treatment | DrugBank Online, accessed August 3, 2025, [https://go.drugbank.com/drugs/DB01018/clinical\_trials?conditions\=DBCOND0041782\&phase\=4\&purpose\=treatment\&status\=completed]
43. Guanfacine as a treatment for ADHD: What to know - Medical News Today, accessed August 3, 2025, [https://www.medicalnewstoday.com/articles/325695]
44. Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) | ClinicalTrials.gov, accessed August 3, 2025, [https://clinicaltrials.gov/study/NCT01081145]
45. Guanfacine ADHD Non-Stimulant Medication: Side Effects, Uses, Dosages, Warnings, accessed August 3, 2025, [https://www.additudemag.com/medication/guanfacine/]
46. Guanfacine vs Lisinopril Comparison - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/compare/guanfacine\-vs\-lisinopril]
47. Guanfacine vs Losartan Comparison - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/compare/guanfacine\-vs\-losartan]
48. The Case for Using Guanfacine Over Clonidine - Clinical Directors Network, accessed August 3, 2025, [https://www.cdnetwork.org/wp\-content/uploads/2017/08/bp\-visit.8\.10\.2017\.pdf]
49. Guanfacine (Intuniv®, Tenex®) - MotherToBaby | Fact Sheets - NCBI, accessed August 3, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK582735/]
50. Study Details | Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder | ClinicalTrials.gov, accessed August 3, 2025, [https://clinicaltrials.gov/study/NCT01238575]
51. Guanfacine's mechanism of action in treating prefrontal cortical disorders: Successful translation across species - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7567669/]
52. A randomized double-blind placebo-controlled trial of Guanfacine Extended Release for aggression and self-injurious behavior associated with Prader-Willi Syndrome | medRxiv, accessed August 3, 2025, [https://www.medrxiv.org/content/10\.1101/2024\.08\.22\.24312419v1]
53. Potential New Treatment for “Brain Fog” in Long COVID Patients - Yale School of Medicine, accessed August 3, 2025, [https://medicine.yale.edu/news\-article/potential\-new\-treatment\-for\-brain\-fog\-in\-long\-covid\-patients/]
54. Search for guanfacine - Clinical Trials register, accessed August 3, 2025, [https://www.clinicaltrialsregister.eu/ctr\-search/search?query\=guanfacine]
55. Guanfacine - Alzheimer's Drug Discovery Foundation, accessed August 3, 2025, [https://www.alzdiscovery.org/uploads/cognitive\_vitality\_media/Guanfacine\-Cognitive\-Vitality\-For\-Researchers.pdf]
56. Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) | ClinicalTrials.gov, accessed August 3, 2025, [https://clinicaltrials.gov/study/NCT01244490?term\=AREA%5BBasicSearch%5D(AREA%5BBasicSearch%5D(AREA%5BBasicSearch%5D(AREA%5BIdSearch%5D(%22NCT00150618%22OR%22NCT00151996%22OR%22NCT00152009%22OR%22NCT00367835%22OR%22NCT00734578%22OR%22NCT00997984%22OR%22NCT01081132%22OR%22NCT01081145%22OR%22NCT01244490%22OR%22NCT01500694%22OR%22NCT01709695%22OR%22NCT02141113%22OR%22NCT03662763%22OR%22NCT04085172%22\))))\&rank\=6]
57. Safety and efficacy of guanfacine extended-release in adults with attention-deficit/hyperactivity disorder: an open-label, long-term, phase 3 extension study, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC7531113/]
58. Tenex and ADHD: Dosage, Side Effects and More - Healthline, accessed August 3, 2025, [https://www.healthline.com/health/adhd/tenex\-adhd]
59. 19-032S016 Tenex Administrative Documents - accessdata.fda.gov, accessed August 3, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/nda/2002/19\-032S016\_Tenex\_Admindocs.pdf]
60. 6 Non-Stimulant ADHD Medications to Consider - Talkspace, accessed August 3, 2025, [https://www.talkspace.com/mental\-health/conditions/articles/non\-stimulant\-adhd\-medications/]
61. What is the role of guanfacine in the treatment of Attention Deficit Hyperactivity Disorder (ADHD)? - Dr.Oracle, accessed August 3, 2025, [https://www.droracle.ai/articles/156775/guanfacine\-for\-adhd]
62. Tenex Dosage Guide - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/dosage/tenex.html]
63. Side Effects of Tenex (guanfacine): Interactions & Warnings - MedicineNet, accessed August 3, 2025, [https://www.medicinenet.com/side\_effects\_of\_guanfacine\-oral/side\-effects.htm]
64. 8 Guanfacine Interactions You Should Know About - GoodRx, accessed August 3, 2025, [https://www.goodrx.com/guanfacine/interactions]
65. Guanfacine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/dosage/guanfacine.html]
66. Guanfacine oral tablet interactions - Optum Perks, accessed August 3, 2025, [https://perks.optum.com/blog/guanfacine\-tablet\-interactions]
67. www.rxlist.com, accessed August 3, 2025, [https://www.rxlist.com/intuniv\-drug.htm\#:\~:text\=Intuniv%20may%20interact%20with%20valproic,may%20contain%20drowsiness%2Dcausing%20ingredients.]
68. Reference ID: 3660379 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 3, 2025, [https://www.accessdata.fda.gov/drugsatfda\_docs/label/2014/022037s010lbl.pdf]
69. Guanfacine extended-release oral tablets - Cleveland Clinic, accessed August 3, 2025, [https://my.clevelandclinic.org/health/drugs/20296\-guanfacine\-extended\-release\-tablets]
70. Guanfacine for irritability, impulsivity, and agitation in elderly patients: A report of two cases, accessed August 3, 2025, [https://www.researchgate.net/publication/360713779\_Guanfacine\_for\_irritability\_impulsivity\_and\_agitation\_in\_elderly\_patients\_A\_report\_of\_two\_cases]
71. Guanfacine for the management of the behavioral manifestations of delirium in older hospitalized adults in - Mental Health Clinician, accessed August 3, 2025, [https://mhc.kglmeridian.com/view/journals/mhcl/15/3/article\-p164\.xml]
72. Guanfacine Use During Pregnancy - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/pregnancy/guanfacine.html]
73. Guanfacine (Intuniv®, Tenex®) - MotherToBaby, accessed August 3, 2025, [https://mothertobaby.org/fact\-sheets/guanfacine/]
74. PSYCHIATRIC MEDICATIONS & PREGNANCY - Maryland Addiction Consultation Service (MACS), accessed August 3, 2025, [https://www.marylandmacs.org/media/SOM/Microsites/MACS/Documents/2\.7\.23\-MACS\-for\-MOMs\-webinar.pdf]
75. The Effects of Drugs used for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) on Pregnancy Outcome and Breast-feeding: A Critical Review - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC9185785/]
76. Guanfacine use while Breastfeeding - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/breastfeeding/guanfacine.html]
77. Guanfacine vs Clonidine: What's the Difference & Which Is Better? - MEDvidi, accessed August 3, 2025, [https://medvidi.com/blog/guanfacine\-vs\-clonidine]
78. Clonidine and guanfacine IR vs ER: Old drugs with “new” formulations in, accessed August 3, 2025, [https://mhc.kglmeridian.com/view/journals/mhcl/4/1/article\-p22\.xml]
79. Clonidine and guanfacine--comparison of their effects on haemodynamics in hypertension, accessed August 3, 2025, [https://pubmed.ncbi.nlm.nih.gov/3887593/]
80. A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder | American Journal of Psychiatry, accessed August 3, 2025, [https://psychiatryonline.org/doi/full/10\.1176/appi.ajp.158\.7\.1067]
81. Clonidine and guanfacine in hypertension - PubMed, accessed August 3, 2025, [https://pubmed.ncbi.nlm.nih.gov/3882307/]
82. Clonidine vs Guanfacine Comparison - Drugs.com, accessed August 3, 2025, [https://www.drugs.com/compare/clonidine\-vs\-guanfacine]
83. Strattera® vs. Intuniv® One Works Better for ADHD? - ClarityX, accessed August 3, 2025, [https://clarityxdna.com/blog/med\-vs\-med/strattera\-vs\-intuniv\-adhd\-medication\-comparison/]
84. Atomoxetine: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 3, 2025, [https://go.drugbank.com/drugs/DB00289]
85. Strattera vs. Intuniv for Childhood ADHD: 7 Notable Differences - GoodRx, accessed August 3, 2025, [https://www.goodrx.com/conditions/adhd/intuniv\-vs\-strattera]
86. Intuniv vs Strattera | Power - Clinical Trials, accessed August 3, 2025, [https://www.withpower.com/guides/intuniv\-vs\-strattera\-ab0d]
87. Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology - PubMed Central, accessed August 3, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3824845/]
88. (PDF) Comparative efficacy and tolerability of medications for Attention-Deficit/Hyperactivity Disorder in children, adolescents and adults: a systematic review and network meta-analysis - ResearchGate, accessed August 3, 2025, [https://www.researchgate.net/publication/326646344\_Comparative\_efficacy\_and\_tolerability\_of\_medications\_for\_Attention\-DeficitHyperactivity\_Disorder\_in\_children\_adolescents\_and\_adults\_a\_systematic\_review\_and\_network\_meta\-analysis]
89. Intuniv vs. Strattera for ADHD: Important Differences and Potential Risks. - GoodRx, accessed August 3, 2025, [https://www.goodrx.com/compare/intuniv\-vs\-strattera]
90. What Are Nonstimulant Medications for ADHD? - Child Mind Institute, accessed August 3, 2025, [https://childmind.org/article/what\-are\-nonstimulant\-medications\-for\-adhd/]
91. Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents | Pediatric Annals - Slack Journals, accessed August 3, 2025, [https://journals.healio.com/doi/10\.3928/19382359\-20241007\-07]
92. Types of Blood Pressure Medications | American Heart Association, accessed August 3, 2025, [https://www.heart.org/en/health\-topics/high\-blood\-pressure/changes\-you\-can\-make\-to\-manage\-high\-blood\-pressure/types\-of\-blood\-pressure\-medications]